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Background: Axonal damage in large myelinated nerve fibres occurs in about 70% of patients with severe sepsis,
known as critical illness polyneuropathy and contributes significantly to an increased short- and long-term morbid-
ity and mortality in this population. Among other pathophysiological mechanisms, autonomic dysregulation, charac-
terized by high concentrations of circulating catecholamines in the presence of impaired sympathetic modulation
of heart and vessels have been discussed. We hypothesize that autonomic small fibre neuropathy play an important
role in autonomic failure.
Methods/Design: Single center, non-randomized, controlled, observational study. Skin biopsies of patients with severe
sepsis and/or septic shock are compared with those of age-matched controls. In order to assess impairment of small
nerve fibres, skin biopsies are taken at onset of severe sepsis, and two and 16 weeks later. Intraepidermal nerve fibre dens-
ities are histologically analyzed using anti protein gene product (PGP) 9.5 immunostaining. In addition, standardized clin-
ical examinations, as Medical Research Council (MRC) scores of muscle strength, Rankin scores, and standardized nerve
conduction studies of the right median nerve, the right tibial nerve, the left fibular nerve, and both sural nerves are per-
formed, to identify critical illness polyneuropathy and to neurophysiologically quantify the damage of large nerve fibres.
Discussion: The study will allow to describe the frequency of small fibre neuropathy in patients with severe sepsis up to
four months after onset of severe sepsis and to evaluate its relationship to critical illness polyneuropathy.
Trial registration: The trial has been registered to the German Clinical Trials Register. The trial registration number is
DRKS-ID: DRKS00000642.
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Severe sepsis and septic shock affect hospitals and health
care systems worldwide and represent the third leading
cause of death in industrialized countries [1]. About 70%
of patients develop critical illness polyneuropathy (CIP)
[2,3], the frequency increases up to 100% in patients
with multi-organ failure [4,5].* Correspondence: hubertus.axer@med.uni-jena.de
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stated.Critical illness polyneuropathy (CIP) and myopathy
(CIM) share the major clinical sign of symmetric and
flaccid weakness of muscles and the absence of deep
tendon reflexes [6-9]. Patients with CIP also show a dis-
tal loss of sensitivity to pain, temperature, and vibration.
Electromyography (EMG) and nerve conduction studies
are the electrophysiological gold standards to confirm
CIP or CIM. Typical signs are reductions in amplitudes
of compound muscle action potentials and/or sensory
nerve action potentials in contrast to preserved nerve
conduction velocity indicating axonal damage [10]. CIPd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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longed weaning times from the respirator [11].
In addition, autonomic dysregulation plays a signifi-
cant role in the acute phase of severe sepsis [12], since it
is characterized by high concentrations of circulating
catecholamines in the presence of impaired sympathetic
modulation of heart and vessels, thus contributing to
circulatory failure in severe sepsis. Even though auto-
nomic dysregulation is associated with increased long-
term mortality rates [13,14], the role of an impairment
of small peripheral nerve fibres has never been investi-
gated. Whereas CIP is quite well studied using electro-
physiological measurements as electromyography and
nerve conduction studies, little information is available
about the impairment of small nerve fibres (C-fibres)
and autonomic nerve fibres in the course of the disease.
Nerve conduction studies are able to measure thick
myelinated nerve fibres only, because these mainly com-
pose compound muscle action potentials and sensory
nerve action potentials. Histopathological data originate
solely from nerve and muscle biopsies [15,16].
Recently, novel methods using skin biopsies have
added a new tool for providing diagnostic information
on small nerve fibres. Skin biopsies are safe, minimally
invasive and painless [17] and can be performed at every
site of the body using a disposable 3 mm diameter
punch and usually no suture is required. Its minimal in-
vasiveness makes skin biopsy a useful tool in clinical
practice for diagnosing and monitoring the progression
of peripheral nerve damage. Intraepidermal nerve fibres
(IENFs) can be labelled with antibodies against protein
gene product (PGP) 9.5 [18,19]. The innervation of der-
mal autonomic structures (sweat glands, blood vessels,
hair follicles) can be detected using antibodies against
adrenergic, noradrenergic, cholinergic, and vasodilata-
tory peptidergic fibres [20]. Therefore, skin biopsy is able
to detect separately and specifically small somatic and
autonomic nerve fibres. Histological measurements are
highly reliable [21] and correlate significantly to stereo-
logically estimated nerve fibre densities [22]. Intraepider-
mal nerve fibre density is a quantitative estimate of the
number of nerve fibres in the histologic sample mea-
sured in nerve fibres per millimeter. Normative values of
intraepidermal nerve fibre density in healthy populations
already exist [23-25]. Quantification of IENF density
closely correlates with clinical symptoms and is more sen-
sitive than sensory nerve conduction studies and sural
nerve biopsies in diagnosing small fibre neuropathy. Diag-
nostic efficiency and predictive values of this technique
are very high (level A recommendation) [18,19].
Although pathophysiological mechanisms of CIP de-
velopment have been described in the past, many as-
pects remain unclear [4,9]. Former studies mainly have
focused on large, thick myelinated nerve fibres, becausethese contribute to muscle weakness. Impairment of
small nerve fibres and autonomic nerve fibres and their
role in autonomic failure is less understood.
Methods/Design
Study design
Single center, non-randomized, controlled, observational
study.
Ethical and research governance approval
The study has been granted ethical approval from the
Ethics Committee of the Friedrich Schiller University
Jena (No. 2771-02/10). Written informed consent is ob-
tained from all patients or their legal representatives.
The study is funded by the German Ministry of Educa-
tion and Research (BMBF), Grant No 01 E0 1002.
Trial duration
The study started in October 2010 and will end in
August 2015. Recruitment of patients started on February
2011 and will proceed until April 2015.
Participants
200 patients with severe sepsis and/or septic shock and
60 age-matched controls. Patients are screened daily for
eligibility by four trained ICU research nurses in one
medical, two surgical and one neurological ICUs, com-
prising a total of 70 beds in Jena University Hospital.
Inclusion and exclusion criteria
Patients with severe sepsis and/or septic shock according
to published criteria [26,27], age ≥ 18 years, severe sepsis
and/or septic shock onset ≥ 4 days, written informed
consent obtained from patients or their legal representa-
tives. Exclusion criteria are history of neuromuscular
disorders, such as polyneuropathy, myasthenia gravis,
myopathy and others), known alcohol abuse, high-dose
steroid therapy before sepsis (≥16 mg/kg body weight
for 5 days), ICU stay ≥8 days, participation in another
clinical study, platelet count < 40 Gpt/l, PTT > 60 s, INR >
1.7, likely to die within less than 24 hours.
Inclusion criteria for the control group are written in-
formed consent. Exclusion criteria are history of neuro-
muscular disorders, known alcohol abuse, high-dose
steroid therapy, platelet count < 40 Gpt/l, PTT > 60 s,
INR > 1.7.
Study visits and interventions
Severe sepsis/septic shock group
Study visits are performed between days 2–5 after severe
sepsis/septic shock onset, and on day 14 and 4 months
later (Table 1).
Table 1 Visits and diagnostic procedures
Visit Time point Diagnostic procedures
1 In the first week after onset of
acute sepsis
1st skin biopsy at thigh and ankle, neurological clinical examination (MRC score of muscle strength, ONLS,
Rankin score), nerve conduction studies, sympathetic skin response
2 2 weeks later 2nd skin biopsy at thigh and ankle, neurological clinical examination, nerve conduction studies, sympathetic
skin response
3 4 months later 3d skin biopsy at thigh and ankle, neurological clinical examination, nerve conduction studies, sympathetic
skin response
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standardized clinical neurological examination including
evaluation of MRC (Medical Research Council) muscle
strength, status of muscle reflexes, Rankin score, and
ONLS (Overall Neuropathy Limitations Scale) [28].
Nerve conduction studies Standardized nerve conduc-
tion studies are carried out at each visit using a portable
electrophysiologic device. The right median nerve, the
right tibial nerve, the left fibular nerve, and both sural
nerves are measured. Motor and sensory nerve re-
sponses are assessed for the right median nerve, motor
responses only for the tibial and fibular nerve, and sen-
sory nerve responses for both sural nerves. Sympathetic
skin responses are measured at hands and feet as a
neurophysiological equivalent of autonomic function.
Skin biopsies Skin biopsies are collected from ankle
and thigh at each visit using a 3 mm biopsy punch.
Bright field microscopy for routine diagnostic purposes
is used to analyse skin biopsies. The biopsied tissue is
cut into 50 μm thick sections and immunostained with
anti-PGP 9.5 antibodies to label small nerve fibres in the
skin. Intraepidermal nerve fibre density is calculated by
the the number of stained nerve fibres crossing the basal
lamina of the skin divided by the length of the epidermal
surface.
Control group
Controls are visited once and get a clinical neurological
examination and skin biopsies taken from ankle and
thigh.
Primary endpoint
Frequency of small fibre neuropathy, characterized as
density of intraepidermal nerve fibers (IENF) derived
from skin biopsies, two weeks after onset of severe sep-
sis/septic shock patients in comparison to controls.
Secondary endpoints
 Frequency of small fibre neuropathy, characterized
as density of intraepidermal nerve fibers (IENF)
derived from skin biopsies, two to five days after
onset of severe sepsis/septic shock in patients whodeveloped CIP in comparison to patients without
CIP development.
 Frequency of small fibre neuropathy, characterized
as density of intraepidermal nerve fibers (IENF)
derived from skin biopsies, 4 months days after
onset of severe sepsis/septic shock in patients who
developed CIP in comparison to patients without
CIP development.
 IENF density in comparison to electrophysiological
measurements, clinical parameters (MRC, ONLS) at
severe sepsis/shock onset, at 2 weeks and at
4 months.Statistical analysis
No data is available about the existence of small fibre
neuropathy in severe sepsis/septic shock patients. Nor-
mative value for mean intraepidermal nerve fibre density
at the ankle is supposed to be 12.4 with a standard devi-
ation of 4.6 [24]. About 60 of 200 patients with severe
sepsis/septic shock may not develop CIP (30%) in con-
trast to 140 (70%) patients with CIP [2]. With a control
group of 60 healthy subjects, a difference of intraepider-
mal nerve fibre density of 2 can be detected in an un-
paired t-test with a two-sided significance level of 5%
and a power of 80%. Analysis of the primary endpoint
will be done using the unpaired t-test. Analysis of the
secondary endpoints will be done using descriptive sta-
tistics and unpaired t-tests, where appropriate, which
will be mainly hypothesis-generating. If applicable, add-
itional analysis using multivariate regression models will
be done. Due to the explorative character of the second-
ary analyses, no α correction will be performed.Discussion
This is to our knowledge the first study to address the
frequency of small fibre neuropathy in patients with se-
vere sepsis/septic shock, treated in intensive care units.
Skin biopsies have become a valuable tool in the evalu-
ation of patients with neuropathy [19] with good evi-
dence of reliable normative data [25]. Detection of an
impairment of small nerve fibers in sepsis may give fur-
ther insights into the pathophysiological role of auto-
nomic neuropathy in patients with severe sepsis/septic
shock [12].
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gest that difficulties in patient recruitment may arise be-
cause of bleeding risks as a contraindication for skin
biopsies. Furthermore, gaining informed consent from
the legal representative of severe sepsis/septic shock pa-
tients is difficult to obtain in the acute care setting and
may limit patient recruitment. Moreover, first results of
the prospective severe sepsis/septic shock registry of the
Centre of Sepsis Control and Care (CSCC) at the study
center Jena University Hospital revealed higher mortality
rates as suspected [29], so that relatively few patients
may be available for follow-up examinations. Finally, the
drop-out rate at 4 months is high due patient’s prefer-
ences and decisions. This is highly important for plan-
ning further studies on long-term sequelae in severe
sepsis/septic shock patients.
Trial status
Recruitment of patients started on February 2011 and
will proceed until April 2015. Currently (July 2013), 40
patients with severe sepsis and/or septic shock and 40
controls have been recruited.
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